EGFR and cancer: Two classes of EGFR inhibitors have been developed for cancer therapy: 1) reversible tyrosine kinase inhibitors, including gefitinib and erlotinib; and 2) EGFR blocking antibodies, including cetuximab and panitumumab [5].